(financialwire.net via COMTEX) --

October 3, 2005 (FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 11.76% on volume of 1,005,536, almost twice its average volume of 644,168, to close at $1.52 after Ernest C. Schlotter, a senior analyst with Investrend Research affiliate SISM Research, and a four-star analyst according to San Francisco-based StarMine, reiterated his Speculative Buy/4 rating for the company and set a new 6-month price target of $2.50.

He said the target upgrade reflected very encouraging results from its latest animal trials which paved the way for human clinical trials to commence in early 2006.

The research is posted at http://www.sism.com and http://www.investrendresearch.com

Schlotter noted in his Research Note that SISM has outlined an investment thesis in its report that shows quite clearly that MIVT is still undervalued (it has a current market cap of only $70.7 million). Despite this fact, the stock has tripled in price since its last report, published on June 27, 2005. Since that time, the company has obtained more recognition in the financial community, which was combined with very promising new and exciting validation of their proprietary coating technologies from many sources in and around the biomedical community.

MIVT has also had very successful results from its latest animal trials and SISM expects human clinical trials to commence in early 2006. Furthermore, Frost & Sullivan, a global growth consulting company singled out MIVT as a leader in the large and important medical coatings sector and MIV Therapeutics won the prestigious Frost & Sullivan 2005 Technology Innovation Award for Advanced Medical Coatings. In addition, MIVT closed a $4.14 million fundraiser in August; the money will be sufficient to support the ongoing needs for the Company's operations and research program and preparations for human clinical trials.

SISM also mentioned in its report MIVT's newest technology breakthrough of its proprietary "SMART" coating technology which was developed entirely at MIVT's research and development facility in Vancouver, Canada. The "SMART" drug delivery system is designed to improve the overall biocompatibility of polymer composites and to increase the control of drug delivery characteristics. Engineering specifications used in this novel system provide considerably improved drug release flexibility, including the option of releasing a wide variety of drugs to address the various needs of a patient's particular pathological condition over extended periods of time.

The planned acquisition of SMT would provide a powerful synergy. SISM forecasts SMT to generate considerable revenues in sales, and estimate the market for the combined entity MIVT/SMT to grow to US$150 million within the next three years. Based on the successful acquisition of SMT and the positive outcome of human clinical trials, SISM Research values MIVT at a market cap of $250 million, which is still a 50% discount to similar comparable companies. SISM Research maintains its Speculative Buy/4 rating and new set a new 6-Month Price Tag of $2.50.

SISM Research, based in Zurich, Switzerland, is a private investment research firm offering high-quality, independent, fundamental research on public companies since 1995. SISM writes, publishes and distributes research coverage, in both English and German, on micro- to small-cap public companies trading on the OTC Bulletin Board, NASDAQ and AMEX. This coverage is geared toward institutional and individual investors in both North America and in German-speaking Europe, a market that represents more than 100 million people. SISM Research is a content provider to Thomson Financials OneAnalytics/FirstCall, to Multex, and Investrend. Both SISM Research and InvesTrend Research subscribe to the "Standards for Independent Research Providers." MIV Therapeutics will pay's SISM Research $1,750 per month over a two-year period solely to ensure independent coverage.

The company's InvestorPower page is at http://www.investrend.com/company/list.asp?sPathParam=yes

For those interested in updates, please write contact@investrend.com with "MIVT" in the subject line.

For up-to-the-minute news, features and links click on http://www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp

The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268

http://www.financialwire.net